TITLE

Transfer from Immediate-Release Disopyramide to Controlled-Release Disopyramide

AUTHOR(S)
DiPersio, David M.; Chow, Moses S. S.
PUB. DATE
February 1987
SOURCE
Angiology;Feb1987 Part 2, Vol. 38, p188
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Simulation of serum disopyramide concentrations during transfer from steady-state immediate-release (IR) disopyramide to a sustained-release disopyramide preparation was performed based on pharmacokinetic parameters obtained from fit disopyramide and serum concentrations measured following an initial dose of controlled-release (CR) disopyramide phosphate. Based on the results of simulation, a typical patient with good cardiac, renal, and hepatic function can be transferred from a q 6 h IR disopyramide to an equivalent daily dose of controlled-release disopyramide administered q 12 h beginning at 6 hours after the final IR disopyramide dose.
ACCESSION #
16479039

 

Related Articles

  • Pharmacologic Evaluation of Standard and Controlled-Release Disopyramide. Siddoway, Lyle A.; Barbey, J. Toby; Roden, Dan M.; Woosley, Raymond L. // Angiology;Feb1987 Part 2, Vol. 38, p184 

    Controlled-release disopyramide offers many potential advantages over the standard formulation for improved patient compliance, possible reduction of concentration-related adverse effects, and predictability of pharmacologic effect. The pharmacology of disopyramide, potential advantages and...

  • Long-Term Use of Controlled-Release Disopyramide in Patients with Severe Ventricular Arrhythmias. Paulk Jr., E. Alan // Angiology;Feb1987 Part 2, Vol. 38, p198 

    Controlled-release (CR) disopyramide phosphate has been available for the past four years for the management of patients with ventricular arrhythmias. The advantages of this preparation over the earlier form have for most patients been striking Improved patient compliance as regards dosing, ease...

  • The Clinical Scope of Disopyramide Seven Years After Introduction -- An Overview. Willis III, Park W. // Angiology;Feb1987 Part 2, Vol. 38, p165 

    Disopyramide phosphate, seven years after its introduction, has proved to be a useful and effective Type IA oral agent for treatment of ventricular arrhythmias. The experience of these seven years has amplified and more sharply defined the initial efficiency and safety issues related to the use...

  • A Review of the Effects of Disopyramide Phosphate on Left Ventricular Function and the Peripheral Circulation. Di Bianco, Robert; Gottdiener, John S.; Singh, Steven N.; Fletcher, Ross D. // Angiology;Feb1987 Part 2, Vol. 38, p174 

    In the absence of preexistent myocardial dysfunction, the risk of producing cardiac decompensation in patients being treated with any of the conventional antiarrhythmic agents is low. The availability of disopyramide for clinical use in 1977 produced optimism for an effective antiarrhythmic...

  • The Pharmacokinetic and Pharmacodynamic Effects of Varying the Free Fraction of Disopyramide. Shaw, Leslie M.; Doherty, John U.; Waxman, Harvey L.; Josephson, Mark E. // Angiology;Feb1987 Part 2, Vol. 38, p192 

    We have evaluated the influence of several factors on the binding of disopyramide to protein in human serum using a new ultrafiltration system and the enzyme multiplied immunoassay technique (EMIT) for disopyramide immuno-assay. From these studies and those of other investigators, we conclude...

  • Enantioselective binding of disopyramide to α1-acid glycoprotein and its variants. Kishino, S.; Itoh, S.; Nakagawa, T.; Miyazaki, K. // European Journal of Clinical Pharmacology;Oct2001, Vol. 57 Issue 8, p583 

    Objective: α1-Acid glycoprotein (AAG) has three main genetic variants, F1, S, and A variants. There are few reports on the correlation between AAG variants and binding activity of drug enantiomers. We studied the differences between the binding characteristics of enantiomers of disopyramide...

  • Rythmodan Retard.  // Royal Society of Medicine: Medicines;2002, p483 

    The article presents information on rhythmodan retard, a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide. It is available as modified-release tablets.

  • Isomide CR.  // Royal Society of Medicine: Medicines;2002, p310 

    The article presents information on isomide CR, a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide (as disopyramide phosphate), and is available as capsules.

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;12/1/2007, Vol. 64 Issue 23, p2406 

    The article features the new drugs and its dosage forms in the U.S. Brimonidine tartrate and timolol maleate opthalmic solution is a combination product that contains adrenergic-receptor agonists and inhibitor for the reduction of elevated intraocular pressure of patients with glaucoma....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics